We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Thrombin Levels Linked to Multiple Sclerosis Progression

By LabMedica International staff writers
Posted on 18 Dec 2013
Results obtained from experiments that tested a novel molecular probe directed at thrombin suggested that measurement of thrombin activity might be exploited for developing sensitive probes for preclinical detection and monitoring of inflammation and progression of multiple sclerosis (MS).

MS, which affects more than 200 million people worldwide, is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged by autoimmune attack, leading to demyelination and scarring as well as a broad spectrum of signs and symptoms. More...


Thrombin is the central protease of the blood-clotting cascade, and beyond its key role in the dynamic process of thrombus formation, thrombin has a pronounced proinflammatory character. Investigators at the Gladstone Institutes of the University of California, San Francisco (USA) had shown previously that blood seeping into the brain due to MS-induced weakening of the blood brain barrier caused a buildup of fibrin in the brain. Fibrin is produced from fibrinogen due to the action of thrombin.

In the current study, the investigators used a mouse MS model (experimental autoimmune encephalomyelitis) to characterize the activity pattern of thrombin over the course of the disease. To determine the level of thrombin, the investigators developed a thrombin-specific "Activatable Cell-Penetrating Peptide" (ACPP), a novel type of molecular probe that delivered a fluorescent agent to regions of the mouse nervous system where thrombin was active.

Results published in the November 29, 2013, online edition of the journal Annals of Neurology revealed that thrombin activity preceded onset of neurological signs, increased at disease peak, correlated with fibrin deposition, microglial activation, demyelination, axonal damage, and clinical severity. Mice with a genetic deficit in prothrombin (the precursor of thrombin) confirmed the specificity of the thrombin probe.

"We already knew that the buildup of fibrin appears early in the development of MS - both in animal models and in human patients, so we wondered whether thrombin activity could in turn serve as an early marker of disease," said senior author Dr. Katerina Akassoglou, professor of neurology at the University of California, San Francisco. "In fact, we were able to detect thrombin activity even in our animal models, before they exhibited any of the disease's neurological signs."

"In the future," said Dr. Akassoglou, "this thrombin-specific ACPP could be developed to one day allow for early patient diagnosis and therapeutic intervention - including a way to effectively monitor how patients are responding to the latest treatments."

Related Links:

Gladstone Institutes



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.